Healthcare Global Enterprises Limited — Investor Meet, 06-03-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: Healthcare Global Enterprises reported a record quarterly revenue of INR 559 crores, up 19% year-over-year. For the nine-month period ending December 31, 2024, total revenue was INR 1,638 crores, reflecting a solid 16% growth. The adjusted EBITDA margin stood at 16.5%, translating to INR 92.3 crores in adjusted EBITDA (up 15% YoY) and a PAT growth of 23%. Noteworthy growth was seen in the oncology segment, particularly after the MG Hospital acquisition, which delivered a 24% revenue increase.

2. **Future Outlook and Growth Drivers**: Management emphasized a long-term growth strategy centered on the oncology sector, particularly with planned expansions of existing centers. Focus areas include personalized treatments through precision oncology and research integration to enhance patient outcomes. They anticipate swift recovery in international patient volumes and aim for greater operational efficiencies.

3. **Order Book and Operational Updates**: The consolidation of MG Hospital operations aims to solidify HCG’s market presence. Key performance indicators showed substantial growth: Kolkata centers grew by 40%, while the South Mumbai center reported a 28% increase. Capacity utilization of LINAC machines reached 60%, and patient bed occupancy improved from 52% to 55%.

4. **Analyst Q&A Insights**:

- *Revenue and Profitability*: Analysts focused on future revenue and margin expectations, with management suggesting EBITDA margins could expand as revenue normalizes post-seasonal dips.

- *Market Position and Competitive Landscape*: Queries about competition highlighted concerns about growing international patient business, but management remains confident about returning volumes.

- *Operational Challenges or Risks*: Management acknowledged potential risks associated with geopolitical factors affecting international patient flows, but expressed optimism for recovery.

- *Capex and Capital Allocation*: Capex is projected at INR 275 crores for FY '25, with a focus on enhancing capacity and operational excellence across centers.

- *Strategic Priorities and Long-Term Vision*: Management reiterated their commitment to enhancing clinical excellence while exploring growth through acquisitions.

5. **Market or Regulatory Updates**: Discussion regarding the recent acquisition of CVC's stake by KKR indicates a strategic shift aimed at long-term growth and strategic realignment, with KKR expected to hold a substantial equity stake post-acquisition.

6. **Strategic Focus Areas**: The call highlighted ongoing initiatives in precision medicine and operational efficiency as key themes. Management's tone was optimistic about future growth, driven by both existing center performance and strategic expansions.

7. **Investor Insight**: The company’s robust financial health, combined with strategic growth initiatives and a focus on operational efficiency, aligns positively for long-term investment consideration. Observations from the Q&A and market dynamics suggest a favorable outlook, supporting a potential buy position due to continued growth prospects in the oncology sector.